Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure

Next Previous
Trial Profile

A randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Allergic rhinitis; Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Registrational; Therapeutic Use
  • Acronyms Grass MATA MPL pivotal trial
  • Sponsors Allergy Therapeutics

Most Recent Events

  • 02 Apr 2025 According to ClinicalTrials.gov by the U.S. National Institutes of Health, the primary endpoints have been replaced with one safety endpoint.
  • 25 Jan 2024 Status changed from active, no longer recruiting to completed.
  • 25 Jan 2024 This trial has been completed in Czech Republic (Global end date: 1 Nov 2023).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top